AstraZeneca PLC Financial Statements (AZN)
|
|
|
|
Report date
|
|
|
22.02.2022 |
21.02.2023 |
20.02.2024 |
18.02.2025 |
24.02.2026 |
|
29.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
37 417 |
44 351 |
45 811 |
54 073 |
58 739 |
|
60 439 |
|
Operating Income, bln rub |
|
|
1 056 |
3 757 |
8 193 |
10 003 |
13 743 |
|
14 315 |
|
EBITDA, bln rub |
? |
|
5 113 |
9 085 |
13 422 |
15 438 |
19 829 |
|
20 467 |
|
Net profit, bln rub |
? |
|
112.0 |
3 288 |
5 955 |
7 035 |
10 255 |
|
10 389 |
|
|
OCF, bln rub |
? |
|
5 963 |
9 808 |
10 345 |
11 861 |
14 575 |
|
14 309 |
|
CAPEX, bln rub |
? |
|
2 200 |
2 571 |
3 778 |
4 586 |
2 810 |
|
5 201 |
|
FCF, bln rub |
? |
|
3 763 |
7 237 |
6 567 |
7 275 |
11 765 |
|
9 109 |
|
Dividend payout, bln rub
|
|
|
3 856 |
4 364 |
4 481 |
4 629 |
5 082 |
|
4 912 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
3 443% |
132.7% |
75.2% |
65.8% |
49.6% |
|
47.3% |
|
|
OPEX, bln rub |
|
|
23 924 |
28 203 |
29 350 |
33 863 |
34 363 |
|
35 054 |
|
Cost of production, bln rub |
|
|
12 437 |
12 391 |
8 268 |
10 207 |
10 633 |
|
11 070 |
|
R&D, bln rub |
|
|
9 736 |
9 762 |
10 935 |
13 583 |
14 232 |
|
14 565 |
|
Interest expenses, bln rub |
|
|
1 276 |
1 330 |
1 589 |
1 682 |
1 694 |
|
1 738 |
|
|
Assets, bln rub |
|
|
105 363 |
96 483 |
101 119 |
104 035 |
114 074 |
|
114 015 |
|
Net Assets, bln rub |
? |
|
39 268 |
37 037 |
39 143 |
40 786 |
48 667 |
|
47 333 |
|
Debt, bln rub |
|
|
30 688 |
29 143 |
28 622 |
30 114 |
29 703 |
|
33 918 |
|
Cash, bln rub |
|
|
6 398 |
6 243 |
5 860 |
5 525 |
5 741 |
|
7 675 |
|
Net debt, bln rub |
|
|
24 290 |
22 900 |
22 762 |
24 589 |
23 962 |
|
26 243 |
|
|
Ordinary share price, rub |
|
|
115.9 |
|
|
130.0 |
175.5 |
|
197.2 |
|
Number of ordinary shares, mln |
|
|
1 418 |
1 548 |
1 562 |
1 550 |
1 550 |
|
1 549 |
|
|
Market cap, bln rub |
|
|
164 275 |
0 |
0 |
201 500 |
272 025 |
|
305 494 |
|
EV, bln rub |
? |
|
188 565 |
22 900 |
22 762 |
226 089 |
295 987 |
|
331 737 |
|
Book value, bln rub |
|
|
-23 116 |
-22 090 |
-18 994 |
-17 416 |
-10 421 |
|
-10 769 |
|
|
EPS, rub |
? |
|
0.08 |
2.12 |
3.81 |
4.54 |
6.62 |
|
6.71 |
|
FCF/share, rub |
|
|
2.65 |
4.68 |
4.20 |
4.69 |
7.59 |
|
5.88 |
|
BV/share, rub |
|
|
-16.3 |
-14.3 |
-12.2 |
-11.2 |
-6.72 |
|
-6.95 |
|
|
EBITDA margin, % |
? |
|
13.7% |
20.5% |
29.3% |
28.6% |
33.8% |
|
33.9% |
|
Net margin, % |
? |
|
0.30% |
7.41% |
13.0% |
13.0% |
17.5% |
|
17.2% |
|
FCF yield, % |
? |
|
2.29% |
|
|
3.61% |
4.32% |
|
2.98% |
|
ROE, % |
? |
|
0.29% |
8.88% |
15.2% |
17.2% |
21.1% |
|
21.9% |
|
ROA, % |
? |
|
0.11% |
3.41% |
5.89% |
6.76% |
8.99% |
|
9.11% |
|
|
P/E |
? |
|
1 467 |
0.00 |
0.00 |
28.6 |
26.5 |
|
29.4 |
|
P/FCF |
|
|
43.7 |
0.00 |
0.00 |
27.7 |
23.1 |
|
33.5 |
|
P/S |
? |
|
4.39 |
0.00 |
0.00 |
3.73 |
4.63 |
|
5.05 |
|
P/BV |
? |
|
-7.11 |
0.00 |
0.00 |
-11.6 |
-26.1 |
|
-28.4 |
|
EV/EBITDA |
? |
|
36.9 |
2.52 |
1.70 |
14.6 |
14.9 |
|
16.2 |
|
Debt/EBITDA |
|
|
4.75 |
2.52 |
1.70 |
1.59 |
1.21 |
|
1.28 |
|
|
R&D/CAPEX, % |
|
|
442.5% |
379.7% |
289.4% |
296.2% |
506.5% |
|
280.1% |
|
|
CAPEX/Revenue, % |
|
|
5.88% |
5.80% |
8.25% |
8.48% |
4.78% |
|
8.60% |
|
| AstraZeneca PLC shareholders |
